Search Results

Mounjaro and Zepbound combined for $11.7 billion in the fourth quarter, which beat analyst consensus of $10.6 billion.

• Gross Profit increased 73% YoY • Gross Margin increased 500 basis points to 68% • Adjusted EBITDA loss reported at $1.46M vs $1.17M in year-ago quarter • Near-term business objectives are focused on preserving cash, stabilizing operations, and securing the financial resources required to support continuity of operations

Akeso, Inc. announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for AK117, a next generation CD47 monoclonal antibody in combination with azacitidine for treatment of patients with newly diagnosed higher-risk myelodysplastic syndromes.

Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117.